12,164 reports of this reaction
1.6% of all INFLIXIMAB reports
#11 most reported adverse reaction
DRUG INTOLERANCE is the #11 most commonly reported adverse reaction for INFLIXIMAB, manufactured by Janssen Biotech, Inc.. There are 12,164 FDA adverse event reports linking INFLIXIMAB to DRUG INTOLERANCE. This represents approximately 1.6% of all 769,608 adverse event reports for this drug.
Patients taking INFLIXIMAB who experience drug intolerance should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INTOLERANCE is a less commonly reported adverse event for INFLIXIMAB, but still significant enough to appear in the safety profile.
In addition to drug intolerance, the following adverse reactions have been reported for INFLIXIMAB:
The following drugs have also been linked to drug intolerance in FDA adverse event reports:
DRUG INTOLERANCE has been reported as an adverse event in 12,164 FDA reports for INFLIXIMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INTOLERANCE accounts for approximately 1.6% of all adverse event reports for INFLIXIMAB, making it a notable side effect.
If you experience drug intolerance while taking INFLIXIMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.